|
1
|
Ho VK, Reijneveld JC, Enting RH, Bienfait
HP, Robe P, Baumert BG and Visser O; Dutch Society for
Neuro-Oncology (LWNO), : Changing incidence and improved survival
of gliomas. Eur J Cancer. 50:2309–2318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Signorovitch J, Li N, Ohashi E, Dastani H,
Shaw J and Orsini L: Overall survival (Os), quality of life (Qol),
and neurocognitive function (Nf) in recurrent glioblastoma
multiforme (Gbm): A systematic literature review. Value Health.
18:A4332015. View Article : Google Scholar
|
|
4
|
A PLK4 inhibitor has single-agent activity
in preclinical tumor models. Cancer Discov. 4:OF112014. View Article : Google Scholar
|
|
5
|
Korzeniewski N, Hohenfellner M and
Duensing S: CAND1 promotes PLK4-mediated centriole overduplication
and is frequently disrupted in prostate cancer. Neoplasia.
14:799–806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shinmura K, Kurabe N, Goto M, Yamada H,
Natsume H, Konno H and Sugimura H: PLK4 overexpression and its
effect on centrosome regulation and chromosome stability in human
gastric cancer. Mol Biol Rep. 41:6635–6644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cunha-Ferreira I, Rodrigues-Martins A,
Bento I, Riparbelli M, Zhang W, Laue E, Callaini G, Glover DM and
Bettencourt-Dias M: The SCF/Slimb ubiquitin ligase limits
centrosome amplification through degradation of SAK/PLK4. Curr
Biol. 19:43–49. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rogers GC, Rusan NM, Roberts DM, Peifer M
and Rogers SL: The SCF Slimb ubiquitin ligase regulates Plk4/Sak
levels to block centriole reduplication. J Cell Biol. 184:225–239.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guderian G, Westendorf J, Uldschmid A and
Nigg EA: Plk4 trans-autophosphorylation regulates centriole number
by controlling betaTrCP-mediated degradation. J Cell Sci.
123:2163–2169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holland AJ, Lan W, Niessen S, Hoover H and
Cleveland DW: Polo-like kinase 4 kinase activity limits centrosome
overduplication by autoregulating its own stability. J Cell Biol.
188:191–198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marina M and Saavedra HI: Nek2 and Plk4:
Prognostic markers, drivers of breast tumorigenesis and drug
resistance. Front Biosci. 19:352–365. 2014. View Article : Google Scholar
|
|
12
|
Rosario CO, Ko MA, Haffani YZ, Gladdy RA,
Paderova J, Pollett A, Squire JA, Dennis JW and Swallow CJ: Plk4 is
required for cytokinesis and maintenance of chromosomal stability.
Proc Natl Acad Sci USA. 107:6888–6893. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mason JM, Lin DC, Wei X, Che Y, Yao Y,
Kiarash R, Cescon DW, Fletcher GC, Awrey DE, Bray MR, et al:
Functional characterization of CFI-400945, a Polo-like kinase 4
inhibitor, as a potential anticancer agent. Cancer Cell.
26:163–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sampson PB, Liu Y, Forrest B, Cumming G,
Li SW, Patel NK, Edwards L, Laufer R, Feher M, Ban F, et al: The
discovery of Polo-like kinase 4 inhibitors: Identification of
(1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl)-1H.indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one
(CFI-400945) as a potent, orally active antitumor agent. J Med
Chem. 58:147–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu B, Yu Z, Qi PP, Yu DQ and Liu HM:
Discovery of orally active anticancer candidate CFI-400945 derived
from biologically promising spirooxindoles: Success and challenges.
Eur J Med Chem. 95:35–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang
Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, et al: Targeting
NEK2 attenuates glioblastoma growth and radioresistance by
destabilizing histone methyltransferase EZH2. J Clin Invest.
127:3075–3089. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Diest PJ, van Dam P, Henzen-Logmans
SC, Berns E, van der Burg ME, Green J and Vergote I: A scoring
system for immunohistochemical staining: consensus report of the
task force for basic research of the EORTC-GCCG. European
organization for research and treatment of cancer-gynaecological
cancer cooperative group. J Clin Pathol. 50:801–804. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mao P, Joshi K, Li J, Kim SH, Li P,
Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, et al:
Mesenchymal glioma stem cells are maintained by activated
glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc
Natl Acad Sci USA. 110:8644–8649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen C, Wang X, Xiong X, Liu Q, Huang Y,
Xu Q, Hu J, Ge G and Ling K: Targeting type Igamma
phosphatidylinositol phosphate kinase inhibits breast cancer
metastasis. Oncogene. 34:4635–4646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu J, Ahuja LG, Meharena HS, Kannan N,
Kornev AP, Taylor SS and Shaw AS: Kinase regulation by hydrophobic
spine assembly in cancer. Mol Cell Biol. 35:264–276. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stransky N, Cerami E, Schalm S, Kim JL and
Lengauer C: The landscape of kinase fusions in cancer. Nat Commun.
5:48462014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim SH, Joshi K, Ezhilarasan R, Myers TR,
Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, et al:
EZH2 protects glioma stem cells from radiation-induced cell death
in a MELK/FOXM1-dependent manner. Stem Cell Reports. 4:226–238.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Minata M, Gu C, Joshi K, Nakano-Okuno M,
Hong C, Nguyen CH, Kornblum HI, Molla A and Nakano I: Multi-kinase
inhibitor C1 triggers mitotic catastrophe of glioma stem cells
mainly through MELK kinase inhibition. PLoS One. 9:e925462014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joshi K, Banasavadi-Siddegowda Y, Mo X,
Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, et
al: MELK-dependent FOXM1 phosphorylation is essential for
proliferation of glioma stem cells. Stem Cells. 31:1051–1063. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gu C, Banasavadi-Siddegowda YK, Joshi K,
Nakamura Y, Kurt H, Gupta S and Nakano I: Tumor-specific activation
of the C-JUN/MELK pathway regulates glioma stem cell growth in a
p53-dependent manner. Stem Cells. 31:870–881. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Habedanck R, Stierhof YD, Wilkinson CJ and
Nigg EA: The Polo kinase Plk4 functions in centriole duplication.
Nat Cell Biol. 7:1140–1146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Macmillan JC, Hudson JW, Bull S, Dennis JW
and Swallow CJ: Comparative expression of the mitotic regulators
SAK and PLK in colorectal cancer. Ann Surg Oncol. 8:729–740. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dzhindzhev NS, Yu QD, Weiskopf K,
Tzolovsky G, Cunha-Ferreira I, Riparbelli M, Rodrigues-Martins A,
Bettencourt-Dias M, Callaini G and Glover DM: Asterless is a
scaffold for the onset of centriole assembly. Nature. 467:714–718.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Tan M, Li L, Pamarthy D, Lawrence TS
and Sun Y: SAK, a new polo-like kinase, is transcriptionally
repressed by p53 and induces apoptosis upon RNAi silencing.
Neoplasia. 7:312–323. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakamura T, Saito H and Takekawa M: SAPK
pathways and p53 cooperatively regulate PLK4 activity and
centrosome integrity under stress. Nat Commun. 4:17752013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun W, Lan X, Zhang H, Wang Z, Dong W, He
L, Zhang T, Zhang P, Liu J and Qin Y: NEAT1_2 functions as a
competing endogenous RNA to regulate ATAD2 expression by sponging
microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis.
9:3802018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kalashnikova EV, Revenko AS, Gemo AT,
Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and Chen HW:
ANCCA/ATAD2 overexpression identifies breast cancer patients with
poor prognosis, acting to drive proliferation and survival of
triple-negative cells through control of B-Myb and EZH2. Cancer
Res. 70:9402–9412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou
L and Guo K: Oncogene ATAD2 promotes cell proliferation, invasion
and migration in cervical cancer. Oncol Rep. 33:2337–2344. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang M, Zhang C, Du W, Yang X and Chen Z:
ATAD2 is overexpressed in gastric cancer and serves as an
independent poor prognostic biomarker. Clin Transl Oncol.
18:776–781. 2016. View Article : Google Scholar : PubMed/NCBI
|
